SF5290

Purpose

• The bill would change Minnesota tax law to require adding back to a taxpayer’s Minnesota income the amount of direct-to-consumer pharmaceutical marketing expenses that are deducted under federal tax rules. This applies to both individual income tax and corporate franchise tax.

Key Definitions

• direct-to-consumer pharmaceutical marketing: advertising and promotional activities aimed at U.S. consumers intended to promote the use, purchase, or prescription of a prescription drug or biologic. This includes TV, radio, print, digital, social media advertising, and patient-directed outreach and disease awareness campaigns funded by a pharmaceutical manufacturer and linked to a specific product.
• pharmaceutical manufacturer: a person or entity involved in producing, preparing, propagating, compounding, or processing prescription drugs or biologics.

Main Provisions

• Adds a new subdivision (21) to Minnesota Statutes 2024 section 290.0131, titled “Pharmaceutical marketing expenses,” with the definitions above.
• Stipulates that the amount deducted under Internal Revenue Code section 162 for direct-to-consumer pharmaceutical marketing is an addition to Minnesota taxable income (i.e., it must be added back for Minnesota tax purposes).

What Changes If Enacted

• Federal deductions for direct-to-consumer pharmaceutical marketing would not fully reduce Minnesota taxable income; the bill would require adding back those deductions to Minnesota’s tax base.
• The policy affects both the individual income tax and the corporate franchise tax.

Potential Implications

• Could raise Minnesota tax liabilities for companies that run DTCA campaigns and claimed corresponding federal deductions.
• May influence how pharmaceutical companies structure marketing expenditures and report them on state filings.

Unknowns/Next Steps

• The excerpt does not include an effective date, transition rules, or any exceptions or thresholds. Details would appear in the full bill language.

Relevant Terms - direct-to-consumer pharmaceutical marketing - advertising - patient-directed outreach - disease awareness campaigns - pharmaceutical manufacturer - prescription drugs - biologics - Internal Revenue Code section 162 (IRC §162) - addition (to Minnesota taxable income) - Minnesota Statutes 2024 section 290.0131 - Minnesota corporate franchise tax - Minnesota individual income tax